

## Special Issue

# Targeting Wnt Signaling in Cancer: Opportunities Abound If We Can Avoid the Sword of Damocles

### Message from the Guest Editors

In the “Topic of Special Interest”, we propose to cover the role of Wnt signaling in cancer, likely with a focus on cancers in solid tumors, especially GI cancers. We will discuss the different driver mutations associated with Wnt-driven cancers (i.e., APC, beta-catenin, Axin, RNF43, etc.) and their association with various cancer types. We plan to also discuss the role of Wnt signaling on the tumor microenvironment and the tumor immune response. Finally, a discussion of efforts to pharmacologically target Wnt signaling to date, including problems and progress, is planned.

### Guest Editors

Prof. Dr. Michael Kahn

Department of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA

Dr. Keane Lai

Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA

### Deadline for manuscript submissions

closed (31 May 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/39958](https://mdpi.com/si/39958)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)